Welcome to PsychU!

Recovery After Initial Schizophrenic Episode – Early Treatment Program (RAISE-ETP) Interview With Dr. John Kane

John M. Kane provides commentary on the results of the Recovery After Initial Schizophrenic Episode – Early Treatment Program (RAISE-ETP) study. The trial compared coordinated specialty care to traditional care of 404 patients with a first-episode of psychosis in a community mental health center setting.

Mark Tacelosky, PharmD, is a Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. Tacelosky received his PharmD from the University of the Sciences in Philadelphia.
John M. Kane, MD, is Senior Vice President for …

Join PsychU today at no cost for access to this and other premium content!

Join today for instant access to all PsychU content, events, and more!

Membership is free!

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.

MRC2.CORP.X.03855 / MRC2.CORP.X.03854